Olive Oil Compound Halted Aggressive Colon Cancer in Mice via Gut Bacteria

If you already reach for extra-virgin olive oil because you have heard it is good for your gut, a new mouse study gives you a much more specific reason to care about where that reputation comes from. Researchers isolated the olive oil compound most responsible for the oil's peppery aftertaste and used it to nearly stop an aggressive, hard-to-treat form of colon cancer from growing and spreading in mice. The detail that has microbiome researchers paying closer attention is this: when the team transferred gut bacteria from the treated mice into untreated mice through a fecal transplant, much of the anti-cancer effect came along with it, suggesting at least part of the compound's power runs through the gut, not just the bloodstream.

Key Takeaways

• Daily oral doses of S-(-)-oleocanthal (OC), a phenolic compound unique to extra-virgin olive oil, shrank tumors from an aggressive, KRAS-mutant colon cancer by more than 97% in mice and nearly eliminated its spread to other organs.
• Fecal transplants from OC-treated mice reproduced almost the same anti-cancer effect in untreated mice, and stripping gut bacteria with antibiotics blunted OC's advantage over an injected version of the same dose, pointing to a real role for the microbiome.
• Every experiment here was in mice, the specific bacteria responsible were not identified, and there is no human dosing or safety data yet.
• The authors calculate a rough human-equivalent dose (about 56 milliliters a day of high-phenolic olive oil) but call it preliminary, not a treatment recommendation.

Oleocanthal Suppressed KRAS-Mutant Colon Tumors in Mice

S-(-)-oleocanthal (OC), the compound behind the sharp, peppery bite at the back of the throat from a good extra-virgin olive oil, suppressed tumor growth by more than 97% in mice carrying an aggressive, KRAS-mutant form of colorectal cancer, compared with untreated animals. The finding comes from a study published in Nutrients by researchers at the University of Louisiana Monroe College of Pharmacy, who implanted human colon cancer cells engineered with the KRAS G13D mutation directly into the cecum (the pouch where the small and large intestine meet) of nude mice, an "orthotopic" setup that places the tumor in its natural location rather than under the skin.

Daily oral OC at 10 milligrams per kilogram for three weeks cut total tumor weight in male mice from 7,404.5 mg in untreated controls to just 178.4 mg, a 97.6% reduction. Female mice did even better, dropping from 6,540.1 mg to 62.6 mg, a 99.1% reduction. Mice getting OC kept a stable body weight throughout, while untreated control mice lost weight as their tumors grew and spread, a sign of worsening disease.

Why an Aggressive KRAS Mutation Matters for Colon Cancer Patients

Colorectal cancer is projected to cause tens of thousands of deaths in the United States this year and remains one of the leading causes of cancer death overall, a burden tracked closely by the American Cancer Society. KRAS mutations drive an estimated 40 to 50% of colorectal cancer cases and are notoriously hard to treat: they make tumors resistant to an entire class of targeted drugs (anti-EGFR therapies) and are linked to worse outcomes overall. The KRAS G13D subtype used in this study is common enough to matter clinically, and unlike some other KRAS mutations, no approved inhibitor exists for it yet, leaving patients with this mutation few targeted options beyond standard chemotherapy.

Antibiotic Depletion and Fecal Transplants Tested the Microbiome's Role

To find out whether gut bacteria were doing part of the anti-cancer work, the researchers ran two complementary experiments: stripping mice of most gut bacteria with a broad-spectrum antibiotic cocktail, and separately transplanting stool from OC-treated donor mice into untreated tumor-bearing recipients. First, they compared oral OC against the identical 10 mg/kg dose delivered by injection three times a week, a route that reaches the bloodstream but skips direct contact with gut bacteria. Injected OC was markedly weaker, cutting tumor weight by only 64.5% in males and 69.9% in females, versus more than 97% for the oral route at the same dose.

When the team also gave oral OC alongside the antibiotic cocktail, tumor suppression dropped only modestly, to 97.1% in males and 96.0% in females, still far ahead of the injected route. The authors note that a single daily antibiotic dose likely did not fully wipe out the fast-regrowing gut bacterial population, so this comparison probably understates, rather than overstates, how much the microbiome contributes.

The clearer test was the fecal transplant. Stool collected daily from healthy donor mice given a higher OC dose (20 mg/kg) was transferred orally into a separate group of tumor-bearing mice whose own gut bacteria had first been depleted. Those recipients saw tumor weight fall by 99.5% in males and 99.4% in females compared with mice that received stool from untreated donors, matching or slightly beating direct oral OC treatment. Metastasis followed the same pattern: mice that received stool from untreated donors developed tumor spread to the liver and intestine in essentially every animal, plus frequent spread to the spleen and kidney, while mice that received stool from OC-treated donors had metastasis almost completely disappear, with only an isolated case or two remaining in a single organ. At the molecular level, tumors from both the oral OC and fecal-transplant groups showed sharply lower levels of two cancer-driving proteins, SMYD2 and EZH2, that help switch on genes tied to tumor growth.

What the Findings Could Mean for People Watching Their Gut Health

For a reader whose interest in gut health is personal, the honest takeaway is narrow but real: this is early evidence that one specific molecule concentrated in high-quality olive oil, not olive oil consumption broadly, may fight an aggressive cancer partly by reshaping gut bacteria rather than acting on tumor cells alone. That mechanism echoes a wider body of research on how gut bacteria shape response to cancer therapy, where fecal transplants have already shown they can shift outcomes in other cancers. The study authors also worked out a rough human-equivalent dose using a standard mouse-to-human conversion: about 0.81 mg/kg, or roughly 56.7 mg of OC daily for a 70 kg adult, which they say would take about 56.7 milliliters (a bit under a quarter cup) of high-phenolic extra-virgin olive oil per day to reach through diet alone. The authors are explicit that this estimate is preliminary, pending actual human pharmacokinetic studies, and it is not a recommendation to dose yourself with olive oil as a cancer treatment.

Where the Study's Evidence Falls Short

The clearest limitation is also the most basic: every experiment here was done in mice, not people, and the authors themselves call the human-dose estimate preliminary until it is tested in real pharmacokinetic and clinical studies. The antibiotic depletion was also incomplete, a single daily dose likely left some gut bacteria intact, so the reported microbiome contribution is probably a floor, not a ceiling. The study did not identify which specific bacterial species are responsible for the transferred anti-cancer effect, only that transplanting the whole community reproduced it. And the safety figures the authors cite, including a mouse oral toxicity threshold above 500 mg/kg and a report of liver toxicity at 20 mg/kg over four months in a different mouse model, come from separate studies, not from this cancer experiment itself, and are a reason for caution rather than reassurance about self-dosing.

What Comes Next for Oleocanthal and Colon Cancer Research

The same research group previously showed oleocanthal fights colon cancer in a simpler under-the-skin tumor model by targeting the same SMYD2-EZH2 pathway, and this study extends that finding to a more realistic tumor location and adds the microbiome angle. The logical next steps, per the authors, are identifying exactly which gut bacteria carry the anti-cancer effect and moving toward human trials to test whether purified oleocanthal, rather than olive oil consumption generally, has a place in colorectal cancer treatment.

Common Questions

Is this the same as just eating more olive oil? No. The effect came from a purified, concentrated dose of one specific compound (oleocanthal) given daily, not from typical dietary olive oil consumption, which contains much lower and more variable amounts of the compound.

Could gut bacteria alone explain the effect, without the compound itself doing anything? No. Direct oral dosing with OC worked on its own, and depleting gut bacteria only partially reduced its effect. The fecal transplant experiments show bacteria contribute, not that they are the whole story.

Is oleocanthal safe to take as a supplement for cancer prevention? There is no human safety or dosing data from this study. The mouse toxicity data the authors cite showed liver damage at higher doses over months, which argues for caution, not self-experimentation, ahead of clinical trials.

Why did the researchers focus on KRAS G13D colon cancer specifically? KRAS mutations make up 40 to 50% of colorectal cancer cases and are resistant to a major class of targeted drugs. The G13D subtype lacks an approved targeted inhibitor, making it a clinically relevant test case for a new potential treatment approach.

References

1. Md Towhidul Islam Tarun, Hassan Y. Ebrahim, Khalid A. El Sayed (2026). Lead Validation of the Olive Phenolic S-(−)-Oleocanthal for Effective Control of KRASG13D-Mutant Colorectal Cancer Progression and Metastasis. Nutrients. https://doi.org/10.3390/nu18162623
2. Simon Manuel Tria, Matthew E. Burge, Vicki L. J. Whitehall (2023). The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Cancers. https://doi.org/10.3390/cancers15082375
3. Erez N. Baruch, Ilan Youngster, Guy Ben-Betzalel, et al. (2021). Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. https://doi.org/10.1126/science.abb5920